Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

The banal has soared arsenic Solid Biosciences advances its cistron therapy improvement programs. On May 7, Solid Biosciences announced that it has begun a Phase 3 proceedings of its cause campaigner SGT-003. The institution plans to behaviour this proceedings successful aggregate countries, including Australia, Canada, US, UK, and the EU zone. The archetypal diligent dosed successful the Phase 3 survey was successful Australia.

Solid Biosciences is processing SGT-003 arsenic a attraction for Duchenne muscular dystrophy. SGT-003 has received fast-track, orphan drug, and uncommon pediatric designations from the FDA.

According to Solid Biosciences, the Phase 3 survey is designed to play a large relation successful supporting assorted regulatory pathways for cistron therapy successful the US and internationally. Notably, SGT-003’s Phase 3 survey joins the ongoing Phase 1/2 proceedings of the cause candidate.

Solid Biosciences Inc (NASDAQ:SLDB) is simply a beingness sciences institution based successful Massachusetts. It is focused connected processing cistron therapies for cardiac and neuromuscular diseases. It targets uncommon diseases with unmet aesculapian needs.

While we admit the imaginable of SLDB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 8 Best Middle East and Africa Stocks to Buy According to Hedge Funds and 10 Undervalued Aerospace and Defense Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.